{
    "protocolSection": {
        "identificationModule": {
            "nctId": "NCT06415487",
            "orgStudyIdInfo": {
                "id": "ACE2016-001"
            },
            "organization": {
                "fullName": "Acepodia Biotech, Inc.",
                "class": "INDUSTRY"
            },
            "briefTitle": "ACE2016 in Adult Subjects With Locally Advanced or Metastatic Solid Tumors Expressing Epidermal Growth Factor Receptor (EGFR)",
            "officialTitle": "A Phase 1 Multicenter Study Evaluating the Safety and Efficacy of ACE2016, an Allogeneic Anti-EGFR Conjugated Gamma Delta T Cell (gdT) Therapy in Adult Subjects With Locally Advanced or Metastatic Solid Tumors Expressing Epidermal Growth Factor Receptor (EGFR)",
            "therapeuticArea": [
                "Oncology and Hematology"
            ],
            "study": "in-adult-subjects-with-locally-advanced-or-metastatic-solid-tumors-expressing-epidermal-growth-factor-receptor-egfr"
        },
        "statusModule": {
            "statusVerifiedDate": "2024-05",
            "overallStatus": "NOT_YET_RECRUITING",
            "startDateStruct": {
                "date": "2024-05-31",
                "type": "ESTIMATED"
            },
            "primaryCompletionDateStruct": {
                "date": "2026-12-18",
                "type": "ESTIMATED"
            },
            "completionDateStruct": {
                "date": "2027-03-25",
                "type": "ESTIMATED"
            },
            "studyFirstSubmitDate": "2024-04-30",
            "studyFirstSubmitQcDate": "2024-05-10",
            "studyFirstPostDateStruct": {
                "date": "2024-05-16",
                "type": "ACTUAL"
            },
            "lastUpdateSubmitDate": "2024-05-10",
            "lastUpdatePostDateStruct": {
                "date": "2024-05-16",
                "type": "ACTUAL"
            }
        },
        "sponsorCollaboratorsModule": {
            "responsibleParty": {
                "type": "SPONSOR"
            },
            "leadSponsor": {
                "name": "Acepodia Biotech, Inc.",
                "class": "INDUSTRY"
            }
        },
        "oversightModule": {
            "isFdaRegulatedDrug": true,
            "isFdaRegulatedDevice": false
        },
        "descriptionModule": {
            "briefSummary": "ACE2016 is an off-the-shelf, allogeneic gamma delta T (gdT) cell therapy derived from healthy donors, that is under investigation for the treatment of Locally Advanced or Metastatic Solid Tumors Expressing Epidermal Growth Factor Receptor (EGFR).\n\nThe ACE2016-001 study is an open-label, Phase I, first-in-human (FIH) study that aims to evaluate the safety and tolerability, persistency, pharmacodynamics and efficacy of ACE2016 in patients with Locally Advanced or Metastatic Solid Tumors Expressing Epidermal Growth Factor Receptor (EGFR)."
        },
        "conditionsModule": {
            "conditions": [
                "Locally Advanced Solid Tumor",
                "Metastatic Solid Tumor"
            ]
        },
        "designModule": {
            "studyType": "INTERVENTIONAL",
            "phases": [
                "PHASE1"
            ],
            "designInfo": {
                "allocation": "NON_RANDOMIZED",
                "interventionModel": "SEQUENTIAL",
                "primaryPurpose": "TREATMENT",
                "maskingInfo": {
                    "masking": "NONE"
                }
            },
            "enrollmentInfo": {
                "count": 30,
                "type": "ESTIMATED"
            }
        },
        "armsInterventionsModule": {
            "armGroups": [
                {
                    "label": "ACE2016 ONLY: 1 DOSE",
                    "type": "EXPERIMENTAL",
                    "description": "ACE2016 dose escalation, monotherapy. Lymphodepleting regimen followed by escalating doses of ACE2016.",
                    "interventionNames": [
                        "Drug: Cyclophosphamide",
                        "Drug: Fludarabine",
                        "Drug: ACE2016"
                    ]
                },
                {
                    "label": "ACE2016 ONLY: 3 DOSES",
                    "type": "EXPERIMENTAL",
                    "description": "ACE2016 recommended dose, monotherapy. Lymphodepleting regimen followed by recommended dose of ACE2016.",
                    "interventionNames": [
                        "Drug: Cyclophosphamide",
                        "Drug: Fludarabine",
                        "Drug: ACE2016"
                    ]
                },
                {
                    "label": "ACE2016 AND PEMBROLIZUMAB: 3 DOSES",
                    "type": "EXPERIMENTAL",
                    "description": "ACE2016 recommended dose, in combination with pembrolizumab. Lymphodepleting regimen followed by recommended dose of ACE2016, giving in combination with pembrolizumab.",
                    "interventionNames": [
                        "Drug: Cyclophosphamide",
                        "Drug: Fludarabine",
                        "Drug: ACE2016",
                        "Drug: Pembrolizumab"
                    ]
                }
            ],
            "interventions": [
                {
                    "type": "DRUG",
                    "name": "Cyclophosphamide",
                    "description": "Lymphodepleting agent",
                    "armGroupLabels": [
                        "ACE2016 AND PEMBROLIZUMAB: 3 DOSES",
                        "ACE2016 ONLY: 1 DOSE",
                        "ACE2016 ONLY: 3 DOSES"
                    ]
                },
                {
                    "type": "DRUG",
                    "name": "Fludarabine",
                    "description": "Lymphodepleting agent",
                    "armGroupLabels": [
                        "ACE2016 AND PEMBROLIZUMAB: 3 DOSES",
                        "ACE2016 ONLY: 1 DOSE",
                        "ACE2016 ONLY: 3 DOSES"
                    ]
                },
                {
                    "type": "DRUG",
                    "name": "ACE2016",
                    "description": "Allogeneic gamma delta T (gdT) cell therapy",
                    "armGroupLabels": [
                        "ACE2016 AND PEMBROLIZUMAB: 3 DOSES",
                        "ACE2016 ONLY: 1 DOSE",
                        "ACE2016 ONLY: 3 DOSES"
                    ]
                },
                {
                    "type": "DRUG",
                    "name": "Pembrolizumab",
                    "description": "Immune checkpoint anti-PD-1 antibody",
                    "armGroupLabels": [
                        "ACE2016 AND PEMBROLIZUMAB: 3 DOSES"
                    ]
                }
            ]
        },
        "outcomesModule": {
            "primaryOutcomes": [
                {
                    "measure": "Incidence of DLTs, AESIs, Grade 3 or higher TEAEs, TEAEs considered related to ACE2016, TEAEs resulting in death, SAEs, related SAEs, and TEAEs leading to treatment discontinuation will be summarized by cohort",
                    "timeFrame": "1 year"
                },
                {
                    "measure": "Change from baseline in clinical laboratory tests results",
                    "description": "Number of subject with change from baseline clinical significant lab findings by cohort (descriptive)",
                    "timeFrame": "1 year"
                },
                {
                    "measure": "Change from baseline in vital signs results",
                    "description": "Number of subjects with change from baseline clinical significant vital signs findings by cohort (descriptive)",
                    "timeFrame": "1 year"
                },
                {
                    "measure": "Recommended Dose (RD)",
                    "timeFrame": "1 year"
                }
            ],
            "secondaryOutcomes": [
                {
                    "measure": "Persistence of ACE2016 before and after administration",
                    "description": "Half-life of ACE2016",
                    "timeFrame": "1 year"
                },
                {
                    "measure": "Measure of anti-ACE2016 antibodies after administration",
                    "description": "Titration of anti-ACE2016 antibodies after administration",
                    "timeFrame": "1 year"
                },
                {
                    "measure": "Objective Response Rate (ORR)",
                    "description": "Proportion of subjects assessed as having a complete response (CR) or partial response (PR) according to RECIST v1.1",
                    "timeFrame": "1 year"
                },
                {
                    "measure": "Disease Control Rate (DCR)",
                    "description": "Number of subjects with a complete response (CR), partial response (PR) or stable disease (SD) as defined by RECIST v1.1",
                    "timeFrame": "1 year"
                },
                {
                    "measure": "Duration Of Response (DOR)",
                    "description": "Duration (time) from the first tumor assessment showing response per RECIST v1.1 to the time of disease progression or death.",
                    "timeFrame": "1 year"
                },
                {
                    "measure": "Progression Free Survival (PFS)",
                    "description": "Duration (time) from first ACE2016 cell infusion to first documentation of disease progression per RECIST v1.1 or death",
                    "timeFrame": "1 year"
                }
            ],
            "otherOutcomes": [
                {
                    "measure": "Pharmacodynamics of ACE2016",
                    "description": "Change from baseline IL2,6,8,10 IFN TNF, and change in TBNK cell subsets.",
                    "timeFrame": "1 year"
                },
                {
                    "measure": "gdT infiltration in tumor mass",
                    "description": "Optional biopsy to examine gdT cell infiltration",
                    "timeFrame": "1 year"
                }
            ]
        },
        "eligibilityModule": {
            "eligibilityCriteria": "Inclusion Criteria:\n\n* Locally advanced unresectable or metastatic solid tumors that have failed at least two lines of therapy (one of which must be targeted therapy)\n* At least one measurable lesion as defined by RECIST v1.1 criteria\n* Eastern Cooperative Oncology Group (ECOG) Performance Status 0-1\n* Adequate hematologic and renal, hepatic and cardiac function\n* Oxygen saturation via pulse oximeter \u226592% at rest on room air\n\nExclusion Criteria:\n\n* Prior treatment with a genetically modified cell therapy product targeting EGFR\n* History of allogeneic transplantation\n* Subjects with active CNS metastases\n* History or presence of clinically relevant Central Nervous System (CNS) disorder (e.g. epilepsy)\n* Clinically significant active infection\n* Human Immunodeficiency Virus (HIV) infection, active hepatitis B infection, or hepatitis C infection.\n* History of malignancies with the exception of certain treated malignancies with no evidence of disease.\n* Primary immunodeficiency disorder\n* Pregnant or lactating female\n* Any medical, psychological, familial, or sociological conditions that, in the opinion of the Investigator or Sponsor Medical Monitor, would impair the ability of the subject to receive study treatment or comply with study requirements, including understanding and rendering of informed consent",
            "healthyVolunteers": false,
            "sex": "ALL",
            "minimumAge": "18 Years",
            "stdAges": [
                "ADULT",
                "OLDER_ADULT"
            ]
        },
        "contactsLocationsModule": {
            "centralContacts": [
                {
                    "name": "Stephanie Chien",
                    "role": "CONTACT",
                    "phone": "+1 415 366 7822",
                    "email": "clinical@acepodiabio.com"
                }
            ],
            "locations": [
                {
                    "facility": "SCRI Denver Drug Development Unit",
                    "city": "Denver",
                    "state": "Colorado",
                    "zip": "80218",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "James Vick",
                            "role": "CONTACT"
                        },
                        {
                            "name": "Jason Henry, MD",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 39.73915,
                        "lon": -104.9847
                    }
                },
                {
                    "facility": "Sarah Cannon Research Institute (SCRI) Oncology Partners",
                    "city": "Nashville",
                    "state": "Tennessee",
                    "zip": "37203",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Emily Lay Petcu",
                            "role": "CONTACT"
                        },
                        {
                            "name": "Meredith Pelster, MD",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 36.16589,
                        "lon": -86.78444
                    }
                }
            ]
        },
        "ipdSharingStatementModule": {
            "ipdSharing": "NO"
        }
    },
    "derivedSection": {
        "miscInfoModule": {
            "versionHolder": "2024-07-30"
        },
        "conditionBrowseModule": {
            "meshes": [
                {
                    "id": "D000009369",
                    "term": "Neoplasms"
                }
            ]
        },
        "interventionBrowseModule": {
            "meshes": [
                {
                    "id": "D000003520",
                    "term": "Cyclophosphamide"
                },
                {
                    "id": "C000582435",
                    "term": "Pembrolizumab"
                },
                {
                    "id": "C000024352",
                    "term": "Fludarabine"
                }
            ],
            "ancestors": [
                {
                    "id": "D000007166",
                    "term": "Immunosuppressive Agents"
                },
                {
                    "id": "D000007155",
                    "term": "Immunologic Factors"
                },
                {
                    "id": "D000045505",
                    "term": "Physiological Effects of Drugs"
                },
                {
                    "id": "D000018501",
                    "term": "Antirheumatic Agents"
                },
                {
                    "id": "D000018906",
                    "term": "Antineoplastic Agents, Alkylating"
                },
                {
                    "id": "D000000477",
                    "term": "Alkylating Agents"
                },
                {
                    "id": "D000045504",
                    "term": "Molecular Mechanisms of Pharmacological Action"
                },
                {
                    "id": "D000000970",
                    "term": "Antineoplastic Agents"
                },
                {
                    "id": "D000019653",
                    "term": "Myeloablative Agonists"
                },
                {
                    "id": "D000074322",
                    "term": "Antineoplastic Agents, Immunological"
                },
                {
                    "id": "D000082082",
                    "term": "Immune Checkpoint Inhibitors"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M6727",
                    "name": "Cyclophosphamide",
                    "asFound": "Effect of",
                    "relevance": "HIGH"
                },
                {
                    "id": "M4225",
                    "name": "Antibodies",
                    "relevance": "LOW"
                },
                {
                    "id": "M349416",
                    "name": "Pembrolizumab",
                    "asFound": "Mg/m2",
                    "relevance": "HIGH"
                },
                {
                    "id": "M10184",
                    "name": "Immunoglobulins",
                    "relevance": "LOW"
                },
                {
                    "id": "M283230",
                    "name": "Fludarabine",
                    "asFound": "Rate",
                    "relevance": "HIGH"
                },
                {
                    "id": "M225513",
                    "name": "Fludarabine phosphate",
                    "relevance": "LOW"
                },
                {
                    "id": "M11900",
                    "name": "Mitogens",
                    "relevance": "LOW"
                },
                {
                    "id": "M10212",
                    "name": "Immunosuppressive Agents",
                    "relevance": "LOW"
                },
                {
                    "id": "M10201",
                    "name": "Immunologic Factors",
                    "relevance": "LOW"
                },
                {
                    "id": "M20604",
                    "name": "Antirheumatic Agents",
                    "relevance": "LOW"
                },
                {
                    "id": "M20942",
                    "name": "Antineoplastic Agents, Alkylating",
                    "relevance": "LOW"
                },
                {
                    "id": "M3820",
                    "name": "Alkylating Agents",
                    "relevance": "LOW"
                },
                {
                    "id": "M1346",
                    "name": "Antineoplastic Agents, Immunological",
                    "relevance": "LOW"
                },
                {
                    "id": "M2342",
                    "name": "Immune Checkpoint Inhibitors",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "ANeo",
                    "name": "Antineoplastic Agents"
                },
                {
                    "abbrev": "ARhu",
                    "name": "Antirheumatic Agents"
                },
                {
                    "abbrev": "All",
                    "name": "All Drugs and Chemicals"
                }
            ]
        }
    },
    "hasResults": false
}